Jefferies cuts target for Elanco Animal Health stock from USD 31 to USD 24

Published on 10/24/2026 at 19:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 10.20 percent to USD 1.37 billion. Elanco Animal Health stock costs EUR 20.05 on October 24, 2026 at 1:04 p.m. CEST.

Analyst target and earnings date

Jefferies cut its target from USD 31.00 to USD 24.00 on October 20, 2026.
Second-quarter revenue reached USD 1.37 billion, up 10.20 percent year over year.
Elanco Animal Health stock costs EUR 20.05 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Third-quarter results are scheduled for November 6, 2026 at 8:00 a.m. EST.

ELAN, US28414H1032, Illustration mit AI erstellt.

Elanco Animal Health (ISIN US28414H1032) faces a lower analyst target after MarketBeat reported on October 20, 2026 that Jefferies cut its target from USD 31.00 to USD 24.00 and downgraded the stock from Buy to Hold. Against the USD 22.52 NYSE price on October 23, 2026, the new target is 6.57 percent higher. Elanco Animal Health was trading at EUR 20.05 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Second-quarter growth sets the backdrop

Elanco reported USD 1.37 billion in second-quarter 2026 revenue, up 10.20 percent from the same period a year earlier, while adjusted earnings per share reached USD 0.34 versus USD 0.27 expected. Benzinga reported on October 8, 2026 that adjusted EBITDA reached USD 288 million, up 21.00 percent year over year.

Price position and valuation

The USD 19.40 to USD 27.98 52-week range places the October 23 NYSE price of USD 22.52 16.50 percent above the low and 19.51 percent below the high. Elanco's market capitalization was USD 11.2 billion, with a negative price-to-earnings ratio of 56.30. The company is listed on the NYSE and is included in the S&P MidCap 400.

What comes next for Elanco?

Elanco has scheduled its third-quarter 2026 results for November 6, 2026 at 8:00 a.m. EST. The company guided for third-quarter revenue of USD 1.195 billion to USD 1.22 billion and adjusted earnings per share of USD 0.19 to USD 0.22.

Peer prices add a measured contrast

Comparison with peers

Elanco: down 0.75 percent, negative price-to-earnings ratio of 56.30, market capitalization USD 11.2 billion.
Zoetis (NYSE, USD): down 1.18 percent, price-to-earnings ratio 13.35, market capitalization USD 33.5 billion.
IDEXX Laboratories (NASDAQ, USD): down 1.13 percent, price-to-earnings ratio 39.69, market capitalization USD 44.1 billion.

Analyst caution meets operating growth

Jefferies' lower target reflects a more cautious view of pricing, while Elanco's second-quarter figures point to continued revenue growth and higher adjusted EBITDA. For investors, the November 6 results will provide the next dated test of whether the raised full-year outlook remains supported by operating performance.

The further course of trading is shown by the continuously updated real-time quote of Elanco Animal Health stock.